Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on June 7th, 2023%
A developer of nanoscale lipid particles for delivering genomic therapies to specific cells and tissue, spun-off from academic labs, is raising $25 million in seed funds. . . . → Read More: Targeted Genetic Nanoparticle Company Gains $25M in Seed Funds
By Alan, on May 24th, 2023%
A global drug maker is acquiring access to a biotechnology company’s precise genome editing techniques to develop new therapies for rare and cardiometabolic disorders. . . . → Read More: Pharma Company Gains Precise Gene Edits in $2B Biotech Deal
By Alan, on May 17th, 2023%
A clinical trial shows a peel-and-stick patch device is as effective as a standard syringe injection in delivering a vaccine that protects against measles and rubella. . . . → Read More: Measles-Rubella Patch Vaccine Shown Effective as Injection
By Alan, on March 23rd, 2023%
Two biotechnology companies are collaborating on creating genetic therapies delivered with lipid nanoscale particles using non-viral mechanisms to reach target cells. . . . → Read More: Moderna, Biotech Partner on Non-Viral Genetic Drug Delivery
By Alan, on March 22nd, 2023%
A new company making antibodies that degrade disease-causing proteins on and outside cell surfaces is raising $50 million in its first venture funding round. . . . → Read More: Start-Up Licenses Protein Therapy Tech, Raises $50M
By Alan, on March 6th, 2023%
An enterprise spun off from university labs is licensing its technology to a drug maker for eye drops with immune-system antibodies to treat dry eye disease. . . . → Read More: Start-Up Licensing Antibody Eye Drops for Dry Eye Disease
By Alan, on March 2nd, 2023%
A university lab and biotechnology company are developing new cancer treatments with therapies that stop RNA activity, delivered by advanced nanoscale particles. . . . → Read More: Business-Academic Team to Create RNA Delivery for Cancer
By Alan, on February 21st, 2023%
A university lab created and licensed to a biotechnology company a model human ovary made of functioning cells for female reproductive health applications. . . . → Read More: Human Ovary Organoid Model Demonstrated, Licensed
By Alan, on February 6th, 2023%
A biotechnology enterprise creating engineered antibodies to treat severe food allergies is raising $40 million in its second venture financing round. . . . → Read More: Allergy Antibody Biotech Gains $40M in New Funds
By Alan, on February 3rd, 2023%
A new enterprise began public operations to provide researchers with better analytical tools for making sense of mountains of complex genomics and related biomedical data. . . . → Read More: Start-Up Creating Software to Simplify Biomedical Analytics
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|